Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa.

scientific article published in April 2016

Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S40256-015-0157-9
P2888exact matchhttps://scigraph.springernature.com/pub.10.1007/s40256-015-0157-9
P698PubMed publication ID26749408

P2093author name stringZhigang Yu
Donglu Zhang
Charles Frost
Frank LaCreta
Wonkyung Byon
Clapton Dias
Jessie Wang
Andrew Shenker
Rebecca A Boyd
Blisse Vakkalagadda
P2860cites workDiscovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood [...]Q27648707
Membrane transporters in drug developmentQ29616802
Apixaban versus warfarin in patients with atrial fibrillationQ29617563
Apixaban metabolism and pharmacokinetics after oral administration to humansQ33373622
Apixaban or enoxaparin for thromboprophylaxis after knee replacementQ34018819
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trialQ34102430
Apixaban versus enoxaparin for thromboprophylaxis after hip replacementQ34156023
Apixaban in patients with atrial fibrillationQ34163710
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjectsQ34285711
The drug efflux-metabolism alliance: biochemical aspects.Q34384318
Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgeryQ34413003
Pharmacokinetic interactions with rifampicin : clinical relevanceQ35185727
Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitorQ35557449
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytesQ35608569
Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixabanQ35666219
Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotypingQ36922212
Pharmacokinetics and metabolic drug interactions.Q37230205
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjectsQ37369329
Effect of activated charcoal on apixaban pharmacokinetics in healthy subjectsQ37653181
Characterization of efflux transporters involved in distribution and disposition of apixaban.Q39199496
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampinQ40851439
In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studiesQ43235385
Oral apixaban for the treatment of acute venous thromboembolismQ43741993
Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.Q46023319
Sulfation of o-demethyl apixaban: enzyme identification and species comparisonQ46170713
Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studiesQ46722053
The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.Q51521480
Tissue distribution and elimination of [14C]apixaban in rats.Q51533087
General derivation of the equation for time to reach a certain fraction of steady state.Q52434488
Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor.Q52838335
P433issue2
P921main subjectpharmacokineticsQ323936
apixabanQ414462
rifampicinQ422652
P304page(s)119-127
P577publication date2016-04-01
P1433published inAmerican journal of cardiovascular drugsQ2555367
P1476titleEffect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa.
P478volume16

Reverse relations

cites work (P2860)
Q90160421A Simple Methodology to Differentiate Changes in Bioavailability from Changes in Clearance Following Oral Dosing of Metabolized Drugs
Q92028447Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Q38960858Apixaban: A Review in Venous Thromboembolism
Q90348789Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care
Q38616215Drug interactions with new oral anticoagulants in elderly patients
Q90211829Drug-Drug Interactions with Direct Oral Anticoagulants
Q38830358Drug-drug interactions of non-vitamin K oral anticoagulants
Q36797336Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
Q37519054New oral anticoagulants and the cancer patient.
Q38194842Oral anticoagulants for Asian patients with atrial fibrillation
Q41083353Pharmacokinetics of apixaban
Q64977733Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation.
Q33729811Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism
Q49850586Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation.
Q91812150Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges
Q37669187The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
Q53622758The renal elimination of apixaban: the totality of data relating to the renal clearance of apixaban in patients with impaired renal function: response to Hellfritzsch et al.
Q26828439The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery

Search more.